Demographics and clinical characteristics
| Characteristic . | All patients (N = 997) . |
|---|---|
| Sex at index∗ | |
| Female | 424 (42.5) |
| Male | 545 (54.7) |
| Undifferentiated | 28 (2.8) |
| Age at index, median (Q1-Q3)†, y | 66.0 (58.0-74.0) |
| Race at index | |
| White | 655 (88.2) |
| Black | 26 (3.5) |
| Asian | 61 (8.2) |
| Multiple | 1 (0.1) |
| Unknown | 254 |
| Geographic region at index | |
| North America | 186 (18.7) |
| Latin America | 216 (21.7) |
| Asia | 50 (5.0) |
| Oceania | 53 (5.3) |
| Europe | 492 (49.3) |
| Type of cancer at diagnosis | |
| Primary MF | 657 (65.9) |
| Secondary MF | 340 (34.1) |
| Platelets (×109/L) at index, median (IQR) | 345.0 (182.0-571.0) |
| Hemoglobin (g/L) at index, median (IQR) | 112.0 (98.0-134.0) |
| Transfusion dependency at index | |
| Yes | 108 (11.7) |
| No | 815 (88.3) |
| Unknown‡ | 74 |
| Time from MF diagnosis to first treatment (mean, median), d | 263, 29 |
| Risk classification method atdiagnosis | |
| IPSS | 194 (32.2) |
| DIPSS | 251 (41.7) |
| DIPSS+ | 139 (23.1) |
| MIPSS | 10 (1.7) |
| Other | 8 (1.3) |
| Unknown‡ | 2 |
| Missing§ | 393 |
| Risk classification at diagnosis|| | |
| Low | 75 (12.5) |
| Intermediate-1 | 192 (32.1) |
| Intermediate-2 | 222 (37.1) |
| High | 109 (18.2) |
| Unknown‡ | 6 |
| Missing§ | 393 |
| HMR mutation at diagnosis | |
| Yes | 89 (50.6) |
| No | 87 (49.4) |
| Unknown‡ | 8 |
| Missing§ | 813 |
| Characteristic . | All patients (N = 997) . |
|---|---|
| Sex at index∗ | |
| Female | 424 (42.5) |
| Male | 545 (54.7) |
| Undifferentiated | 28 (2.8) |
| Age at index, median (Q1-Q3)†, y | 66.0 (58.0-74.0) |
| Race at index | |
| White | 655 (88.2) |
| Black | 26 (3.5) |
| Asian | 61 (8.2) |
| Multiple | 1 (0.1) |
| Unknown | 254 |
| Geographic region at index | |
| North America | 186 (18.7) |
| Latin America | 216 (21.7) |
| Asia | 50 (5.0) |
| Oceania | 53 (5.3) |
| Europe | 492 (49.3) |
| Type of cancer at diagnosis | |
| Primary MF | 657 (65.9) |
| Secondary MF | 340 (34.1) |
| Platelets (×109/L) at index, median (IQR) | 345.0 (182.0-571.0) |
| Hemoglobin (g/L) at index, median (IQR) | 112.0 (98.0-134.0) |
| Transfusion dependency at index | |
| Yes | 108 (11.7) |
| No | 815 (88.3) |
| Unknown‡ | 74 |
| Time from MF diagnosis to first treatment (mean, median), d | 263, 29 |
| Risk classification method atdiagnosis | |
| IPSS | 194 (32.2) |
| DIPSS | 251 (41.7) |
| DIPSS+ | 139 (23.1) |
| MIPSS | 10 (1.7) |
| Other | 8 (1.3) |
| Unknown‡ | 2 |
| Missing§ | 393 |
| Risk classification at diagnosis|| | |
| Low | 75 (12.5) |
| Intermediate-1 | 192 (32.1) |
| Intermediate-2 | 222 (37.1) |
| High | 109 (18.2) |
| Unknown‡ | 6 |
| Missing§ | 393 |
| HMR mutation at diagnosis | |
| Yes | 89 (50.6) |
| No | 87 (49.4) |
| Unknown‡ | 8 |
| Missing§ | 813 |
The data are presented as n (%) unless stated otherwise. Percentages were calculated on known information. Patients with data in an "unknown" category or missing data were excluded.
DIPSS, Dynamic International Prognostic Scoring System; HMR, high molecular risk; MF, myelofibrosis; MIPSS, Mutation-Enhanced International Prognostic Scoring System.
Index defined as first date of the initial treatment in either drug or procedure.
Patients who were >89 years of age were not included in the calculation.
Unknown category was available in the electronic case form for sites to select in case there was no corresponding information available in the patient chart.
Missing category may include patients who did not complete the respective testing or classifications or who had missing information for the respective question.
Pooled from the risk classification methods, namely IPSS, DIPSS, DIPSS+, MIPSS, and other.